SOURCE: Orgenesis Inc.

Orgenesis Inc.

October 20, 2016 10:19 ET

Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting

GERMANTOWN, MD--(Marketwired - Oct 20, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company, announced that Orgenesis CEO, Vered Caplan, will present at the T1D Exchange 4th Annual Meeting, which is being held at the Royal Sonesta Hotel in Boston, Massachusetts on October 21, 2016. Ms. Caplan will speak on the panel "Cellular and Biopharmaceutical Innovations."

The T1D Exchange Annual Meeting is designed to bring together the members -- global diabetes stakeholders from industry, foundation, investment and research -- to foster collaborations and generate new ideas that can improve outcomes in Type 1 Diabetes. The T1D Exchange Annual Meeting convenes more than 175 key industry participants to exchange unique perspectives and robust ideas around innovations in care. Together, these stakeholders will explore important topics including innovations in understanding the origin of T1D, cellular and biopharmaceutical innovations, device, digital health solutions and decision-making support and translating innovations.

About Orgenesis Inc.

Orgenesis is a fully integrated cell therapy and regenerative medicine company. The Company is providing manufacturing services for other cell therapy markets in such areas as cell-based cancer immunotherapies and autoimmune diseases. In addition, through its subsidiary, Orgenesis Ltd, the Company is developing a cure for diabetes using a novel "cellular trans-differentiation" technology that transforms an insulin-dependent patient's own adult cells into functional insulin producing cells. The Company has demonstrated that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult cells can be transformed into fully functional, beta cell-like insulin producing cells. Orgenesis Ltd has an exclusive license from Tel Hashomer Hospital for intellectual property directed to the cellular trans-differentiating technology.

Contact Information